TIDMERGO

RNS Number : 3139I

Ergomed plc

01 April 2020

PRESS RELEASE

Total Voting Rights

Guildford, UK - 1 April 2020: In accordance with the Financial Conduct Authority's Disclosure Guidance and Transparency Rules ("DTRs"), Ergomed plc (the "Company") announces the following information.

The Company's issued share capital as at 31 March 2020 consisted of 48,173,151 ordinary shares of 1p each, none of which were held in treasury. Each ordinary share in the capital of the Company carries one voting right.

The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the DTRs.

ENDS

Enquiries:

 
 Ergomed plc                                           Tel: +44 (0) 1483 402 
                                                                         975 
 Miroslav Reljanović (Executive Chairman) 
 Richard Barfield (Chief Financial Officer) 
 
 Numis Securities Limited                          Tel: +44 (0) 20 7260 1000 
 Freddie Barnfield / Huw Jeremy (Nominated 
  Adviser) 
 James Black (Broker) 
 
 Consilium Strategic Communications - for          Tel: +44 (0) 20 3709 5700 
  UK enquiries 
 Chris Gardner / Sue Stuart                      ergomed@consilium-comms.com 
 Matthew Neal / Olivia Manser

About Ergomed plc

Ergomed provides specialist services to the pharmaceutical industry spanning all phases of clinical development, post-approval pharmacovigilance and medical information. Ergomed's fast-growing, profitable services business includes an industry leading suite of specialist pharmacovigilance (PV) solutions, integrated under the PrimeVigilance brand, a full range of high-quality contract research and trial management services under the Ergomed brand (CRO), and an internationally recognised specialist expertise in orphan drug development, under PSR. For further information, visit: http://ergomedplc.com .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

TVRJBMRTMTJJBPM

(END) Dow Jones Newswires

April 01, 2020 02:00 ET (06:00 GMT)

Ergomed (LSE:ERGO)
Historical Stock Chart
From Apr 2024 to May 2024 Click Here for more Ergomed Charts.
Ergomed (LSE:ERGO)
Historical Stock Chart
From May 2023 to May 2024 Click Here for more Ergomed Charts.